Arrowhead Research's top executive this week reaffirmed that the firm's subsidiary Calando Pharmaceuticals is poised to complete enrollment in a phase I trial of its siRNA-based cancer drug CALAA-01 shortly and to strike its first industry partnership before the end of 2010.

"If data from the [ongoing] clinical trial continue to be positive, the value of such a deal could increase as the trial progresses," Arrowhead President and CEO Christopher Anzalone said in a letter to company shareholders.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.